LBMON196 A Randomized Controlled Trial Of Vosoritide In Infants And Toddlers With Achondroplasia

BACKGROUND: Vosoritide increases annualized growth velocity (AGV) in children with achondroplasia aged 5 to 18 years. This global, phase 2, randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of vosoritide on growth in children with achondroplasia aged 3 months to &l...

Descripción completa

Detalles Bibliográficos
Autores principales: Savarirayan, Ravi, Wilcox, William W, Harmatz, Paul, III, John Phillips, Polgreen, Lynda E, Tofts, Louise, Ozono, Keiichi, Arundel, Paul, Irving, Melita, Bacino, Carlos A, Basel, Donald, Bober, Michael B, Charrow, Joel, Mochizuki, Hiroshi, Kotani, Yumiko, Saal, Howard M, Jeha, George, Han, Lynn, Fisheleva, Elena, Huntsman-Labed, Alice, Day, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625654/
http://dx.doi.org/10.1210/jendso/bvac150.1225

Ejemplares similares

Ejemplares similares